Evidence map›Paper›PMID 35514270›Full record

ArticleDiabetic medicine : a journal of the British Diabetic Association2022

Protease-activated receptor-mediated platelet aggregation in patients with type 2 diabetes on potent P2Y

Benjamin Panzer, Patricia P Wadowski, Kurt Huber, Simon Panzer, Thomas Gremmel

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetic medicine : a journal of the British Diabetic Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Protease-activated receptor-mediated platelet aggregation in patients with type 2 diabetes on potent P2YDiabetic medicine : a journal of the British Diabetic Association · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Benjamin PanzerDepartment of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Patricia P WadowskiDepartment of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Kurt HuberSigmund Freud University, Medical School, Vienna, Austria.
Simon PanzerDepartment of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria.
Thomas GremmelDepartment of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Sigmund Freud Privatuniversität Wien · ATInstituto Benjamin Constant · BRLandesklinikum Korneuburg · ATMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntiplatelet therapy is a cornerstone in the secondary prevention of ischemic events following percutaneous coronary intervention (PCI). The new P2Y MATERIALS AND

methodsWe compared P2Y

resultsOverall, there were no differences of P2Y

conclusionPrasugrel and ticagrelor inhibit P2Y

Indexed as

Acute Coronary SyndromeDiabetes Mellitus, Type 2Percutaneous Coronary InterventionAdenosineHumansPlatelet AggregationPlatelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsReceptors, Proteinase-ActivatedTicagrelorAdenosinePlatelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsReceptors, Proteinase-ActivatedTicagreloracute coronary syndromeantiplatelet therapydiabetesplatelet thrombin receptorsprasugrelticagrelor

Identifiers

PMID35514270
PMCPMC9546030
OpenAlexW4229000967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.